BIOATLA INC (BCAB) Stock News

USA - Nasdaq - NASDAQ:BCAB - US09077B1044 - Common Stock

0.8238 USD

-0.02 (-2.85%)

Last: 12/5/2025, 8:04:24 PM

0.8499 USD

+0.03 (+3.17%)

After Hours: 12/5/2025, 8:04:24 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BCAB Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill - Mentions: BEAT CLSD YCBD ADTX ...

News Image

Curious about the stocks that are showing activity after the closing bell on Friday?

15 days ago - By: Chartmill - Mentions: DK BEAT OC IFRX ...

News Image

Get insights into the top gainers and losers of Friday's after-hours session.

16 days ago - By: BioAtla, Inc.

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

18 days ago - By: Benzinga - Mentions: IBIO ENGN IMCC VREX ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

23 days ago - By: The Motley Fool

BioAtla (BCAB) Q3 2025 Earnings Call Transcript

23 days ago - By: BioAtla, Inc.

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

24 days ago - By: Benzinga

What's Next: BioAtla's Earnings Preview

a month ago - By: BioAtla, Inc.

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

a month ago - By: BioAtla, Inc.

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

2 months ago - By: BioAtla, Inc.

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

2 months ago - By: BioAtla, Inc.

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

4 months ago - By: The Motley Fool

BioAtla (BCAB) Q2 Loss Narrows 27%

4 months ago - By: BioAtla, Inc.

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

5 months ago - By: BioAtla, Inc.

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO)

7 months ago - By: BioAtla, Inc.

BioAtla to Participate in the Citizens Life Sciences Conference

7 months ago - By: BioAtla, Inc.

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

8 months ago - By: BioAtla, Inc.

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

8 months ago - By: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

8 months ago - By: BioAtla, Inc.

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

9 months ago - By: BioAtla, Inc.

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

9 months ago - By: BioAtla, Inc.

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

a year ago - By: BioAtla, Inc.

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

a year ago - By: BioAtla, Inc.

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting